Clinical trial

Positron Emission Tomography (PET) Study With [11C]AZD2995 and [11C]AZD2184, Candidate PET Ligands for β Amyloid

NCT00692705

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Radioligand (11C)AZD2995 Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Radioligand (11C)AZD2184 Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Positron Emission Tomography (PET) Study With [11C]AZD2995 and [11C]AZD2184, Candidate PET Ligands for β Amyloid

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE1

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2008-01-01

PhasePHASE1

Conditions

Alzheimer´s Diseaseunresolved

Interventions

Radioligand (11C)AZD2995DRUG

Radioligand (11C)AZD2184DRUG

Sponsors & collaborators

AstraZenecalead sponsor

Mapped research locations

StockholmSweden1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00692705 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.